echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Biotay Adalimumab adds "children's plaque psoriasis" indication

    Biotay Adalimumab adds "children's plaque psoriasis" indication

    • Last Update: 2021-04-29
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On the evening of February 21st, Biotech issued an announcement stating that it had recently received the "Drug Supplementary Application Approval Notice" for adalimumab injection (trade name: Glaly®) approved and issued by the State Food and Drug Administration.


    Data show that Glorious® is a biosimilar of adalimumab developed by Biotech, which is a recombinant fully human monoclonal antibody expressed by CHO cells.


    As of the announcement date, the approved indications for Glorious® are ankylosing spondylitis, rheumatoid arthritis, psoriasis, Crohn's disease, uveitis and plaque psoriasis in children.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.